The Food and Drug Administration (FDA) has expanded the approval of Furoscix® (furosemide injection) to include the treatment of edema in patients with ...
Pharmaceutical Technology on MSN5d
FDA approves scPharmaceuticals’ Furoscix sNDA for oedema in CKDThe US Food and Drug Administration (FDA) has approved scPharmaceuticals’ supplemental new drug application (sNDA) for ...
Pharmaceuticals (SCPH) announced that the FDA has approved the supplemental new drug application for Furoscix to expand the indication to ...
(RTTNews) - scPharmaceuticals Inc. (SCPH) announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for FUROSCIX to expand the indication ...
Last week’s significant research news included positive new Phase III data on Tezspire in nasal polyps from Amgen and ...
Cardiorenal specialist scPharmaceuticals has won US Food and Drug Administration (FDA) approval for its supplemental New Drug Application (sNDA) for Furoscix (furosemide injection) to expand the ...
Heart Failure-Focused scPharmaceuticals Secures FDA Approval For Expanded Use Of Furoscix, Receives Funding To Expand Commercialization FDA approves scPharmaceuticals' expanded Furoscix indication ...
Furoscix is expected to be available for CKD patients in April 2025. The Food and Drug Administration (FDA) has expanded the approval of Furoscix ® (furosemide injection) to include the treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback